(0.31%) 5 115.87 points
(0.31%) 38 359 points
(0.34%) 15 982 points
(-0.88%) $83.11
(5.77%) $2.03
(0.37%) $2 355.90
(0.48%) $27.67
(4.02%) $959.20
(-0.22%) $0.933
(-0.40%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $11.17
発行日: 15 2月 2024 @ 05:35
リターン: 91.58%
前回のシグナル: 2月 15 - 04:36
前回のシグナル:
リターン: 1.92 %
Live Chart Being Loaded With Signals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors...
Stats | |
---|---|
本日の出来高 | 180 193 |
平均出来高 | 2.15M |
時価総額 | 1.82B |
EPS | $-0.390 ( 2024-03-21 ) |
次の収益日 | ( $-0.370 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.76 |
ATR14 | $0.00400 (0.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Leamon Christopher P | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Leamon Christopher P | Buy | 63 700 | Restricted Stock Units |
2023-08-31 | Leamon Christopher P | Buy | 11 957 | Common Stock |
2024-01-04 | Crowley John J | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Crowley John J | Buy | 63 700 | Restricted Stock Units |
INSIDER POWER |
---|
99.99 |
Last 91 transactions |
Buy: 6 470 725 | Sell: 164 236 |
ボリューム 相関
Fusion Pharmaceuticals 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Fusion Pharmaceuticals 相関 - 通貨/商品
Fusion Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $2.07M |
総利益: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2023 |
収益: | $2.07M |
総利益: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2022 |
収益: | $1.46M |
総利益: | $-57.43M (-3 931.14 %) |
EPS: | $-2.00 |
FY | 2021 |
収益: | $1.44M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.884 |
Financial Reports:
No articles found.
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。